Pipeline

POTENT AND SAFE CHEMOKINE ANALOGUES FOR CANCER, NEUROLOGY, AND INFECTIOUS DISEASES

Orion Biotechnology is developing chemokine analogues to address unmet needs in oncology, neuroinflammation, and infectious diseases. We are able to generate highly selective, potent, and safe molecules that are designed to disrupt the chemokine / chemokine receptor interactions that underly these diseases.

Programme

indication

Phase

OB-002O

Oncology

Pre-Clinical

OB-002H

HIV

Clinical Ph1

OB-002M

Neurology

Pre-Clinical

Discovery Platform

Undisclosed Target

Discovery

Programme

Indication

Discovery

Pre-clinical

Clinical Trials
Phase 1       Phase 2      Phase 3

OB-002O

oncology

OB-002H

HIV

OB-002M

Neurology

Discovery platform

Undisclosed Target

OB-002

Orion’s lead molecule (OB-002) is a 69 amino acid analogue of RANTES which the is the ligand for the CCR5 receptor. OB-002 was generated through a rigorous evaluation of thousands of RANTES analogues and lead optimization was conducted to identify a molecule with high binding affinity, excellent potency, and minimal potential for off-target toxicity. The mechanism of action proposed for OB-002 is that the molecule binds to the CCR5 receptor and blocks all downstream signaling and associated immunological events. More specifically in the context of cancer, it is thought that OB-002, like other CCR5 antagonists, will significantly reduce the influx of immunosuppressive T cells into the tumor microenvironment (TME) leading to restoration of antitumor activity within the TME. OB-002 has a best-in-class profile based on in vitro potency and has demonstrated an excellent safety profile in completed animal studies that have included single and multiple topical and intravenous administration of OB-002. Preclinical efficacy studies of OB-002 have shown significant activity in oncology, neuroinflammation, and HIV infection. A topical formulation of OB-002 will initiate Phase 1 evaluation in Q4 2019 and Phase 1 oncology studies are anticipated to start in Q1 2021. Based on preclinical data, we believe that OB-002 has the potential to be efficacious as a monotherapy agent or in combination with other immunotherapy or chemotherapy agents.

Discovery platform

Orion has developed a unique and proprietary discovery platform that will allow us to accelerate the identification and lead optimization of chemokine analogues and other small proteins in a highly cost-efficient fashion. Current efforts are focused on the identification of novel chemokine analogues for the treatment of inflammatory bowel disease.

Global Headquarters

343 Preston Street

11th floor,

Ottawa, On K1S 1N4

CANADA

Switzerland

Campus Biotech

Innovation Park

Avenue de Sécheron 15

1202 Genève

SWITZERLAND

Poland

Orion Biotechnology

PolandSP. Z.O.O.

UI Bobrzyńskiego 14

30-348 Krakôw

POLAND

CONTACT:  info@orionbiotechnology.com

contact us

Leave  us a message and we will try to respond by the next business day

ORION Logo Pantone(375x133)

Our Headquarters

343 Preston Street

11th floor,

Ottawa, ON K1S 1N4

CANADA

info@orionbiotechnology.com

contact us

Leave  us a message and we will try to respond by the next business day

ORION Logo Pantone(375x133)

Our Headquarters

343 Preston Street

11th floor,

Ottawa, ON K1S 1N4

CANADA

info@orionbiotechnology.com